In order to qualify for the discount pricing you must be a Sam's PLUS member. That privilege will cost you $100.00 vs $45.00 for a standard annual membership.
That wasn't meant to be funny.
Your bros should know better than to destroy the hood.
I know of one less CVS Pharmacy in Baltimore MD that won't be selling Qsymia anytime soon.
The crowds at Sam's have become unruly and the governor has declared a state of emergency.
Just drove by Sam's Club and the crowds are already camping out on the side walk to be first in line to get their discounted Qsymia.
NET FLIX has a much watch documentary on OBESITY titled "FED UP". This documentary reveals the root cause for the epidemic rise in obesity. It was eye opening to say the least. Do watch.
Is that your opinion or is it a known fact that some pharmacies report every 2 weeks? It is my understanding that prescription data is tracked on a daily basis.
Rup had a full time job filming upskirt video's from below the New Jersey boardwalk. It abruptly ended when he was caught and beaten to a pulp. Rest assured, as soon as the casts come off he'll be back under the boardwalk.
Sympathomimetic agents for use in the present invention and their general clinical uses or effects are set forth in Table 1.
TABLE-US-00001 TABLE 1 Sympathomimetic Agents and Clinical Uses Thereof General structure: Main Clinical Uses Ring
Conditions of particular interest for which the invention finds utility include overweight, obesity and conditions often associated with and/or caused by excess weight and obesity. The combination of topiramate and phen in the dosages provided herein give rise to significant therapeutic effects and reduced adverse effects, making these pharmaceutical combinations extremely effective therapeutics, especially in the treatment of overweight, obesity and/or related conditions, including conditions associated with and/or caused by excess weight or obesity per se. Subjects suitable for treatment with the subject combination therapy treatment regimen thus include individuals suffering from conditions associated with obesity, such conditions including, without limitation:
diabetes, insulin resistance, and impaired glucose tolerance;
respiratory problems such as pulmonary hypertension, asthma, and shortness of breath;
dyslipidemia, e.g., high cholesterol, high levels of triglycerides, etc.;
osteoarthritis and other orthopedic problems;
adverse conditions related to sleep, including sleep apnea and loud snoring;
menstrual irregularities, infertility, and complications in pregnancy;
high blood pressure, i.e., hypertension;
cardiovascular problems such as coronary artery disease and other heart trouble;
stroke, particularly thrombotic stroke and deep vein thrombosis (DVT);
metabolic disorders such as hypoalphalipoproteinemia, familial combined hyperlipidemia, and Syndrome X, including insulin-resistant Syndrome X; and
colon, rectal, renal, esophageal, gallbladder, pancreatic, prostate, breast, uterine, ovarian, endometrial, and cervical cancers.
Most or all of these problems are relieved or improved by permanent significant weight loss.
Teva has signed a royalty license with Pfizer to sell a generic Viagra effective Dec. 2017. Doubt they can sell it too cheap since they have to pay a royalty on product sales to Pfizer.
Lets me separate fact from fiction. There will be only ONE milestone paid Q1 and that will be 13M for the EU Spedra 15 minute label acceptance.
Licensing and milestones for Stendra/Stedra totals 466M.
Vivus has received 106M to date..
360M remains upon reaching milestone
Spedra licensing deals for Asia and Latin America coming to a conclusion
The 360M excludes any Latin America and Asian licensing deals.
Vivus anticipates the need to raise cash. No timeline given. Will depend on sales.
Cash burn 20M per Q.
CVOT trial will cost 180/220M over 5 years.
Why are you complaining about the Endo deal? We now know they have a minimum of 230 contract reps marketing Stendra which is 80 more than Auxilium. What we don't know is how many company Endo reps are involved in marketing. Could be 500, could be 1000, could be none.
This 230 shared contract sales force will be functional by May 1. Endo may have its own sales force to supplement the shared contract sales force but that's still an open question. Too bad Seth doesn't think this info is news worthy.
I can guarantee you that you won't see any Stendra or Spedra sales milestone being achieved anytime soon.
The US 15-minute milestone was recognized Q3 2014 not Q4 2014. Michael is not correct because he's inflated his estimate by 15.1M for a payment that was already booked in Q3 2014.
No one disputes the EU 15 minute milestone of 10.6M in Q1 2015.
FROM THE 10Q.........Q3 2014
For the three months ended September 30, 2014, the Company recognized $15.1 million in license and milestone revenue primarily attributable to milestone revenue related to the approval of the Time of Onset Claim .
Under the Menarini License Agreement, we are entitled to a $10.0 million Euro..... (10,652,000. USD) milestone payment related to the January 2015 adoption by the EC of the commission implementing decision amending the marketing authorization.
FROM THE 10Q
For the three months ended September 30, 2014, the Company recognized $15.1 million in license and milestone revenue primarily attributable to milestone revenue related to the approval of the Time of Onset Claim in the US.